COVID vaccine delivered to different States

Covaxin has equivalent immunogenicity against UK-variant and circulating strains of SARS-Cov2 in India: ICMR

Indian Council of Medical Research has said that COVID-19 vaccine Covaxin has equivalent immunogenicity against the UK-variant and circulating strains of SARS-Cov2 in India. Covaxin is developed by Bharat Biotech in collaboration with ICMR. The UK-variant of SARS-Cov-2 with its all signature mutations were isolated and cultured in the world successfully for the first time at ICMR-NIV which was used for testing.

Published by

TaxConcept

Tax Concept is a dedicated team of financial writers, legal analysts, and tax professionals committed to breaking down complex Indian corporate updates. From real-time GST amendments and crucial Income Tax judgements to EPFO schemes and corporate law updates, TaxConcept serves as a reliable, authoritative guide for chartered accountants, businesses, and everyday taxpayers seeking absolute compliance clarity.

Reply